Eli Lilly stock climbs on gross margin beat, raised 2024 revenue outlook By
2024-04-30 20:20:03
more 
1237

Eli Lilly & Co. (NYSE:) saw its shares jump 5.4% in premarket trading Tuesday after the pharmaceutical giant reported better-than-expected earnings and gross margin for the fiscal Q1 2024.

Specifically, Eli Lilly posted earnings per share (EPS) of $2.58, beating the analysts' expectations of $2.48. However, the company's revenue for the quarter was $8.77 billion, falling short of the consensus estimate of $8.94 billion.

Importantly, the company's gross margin improved significantly, reaching 80.9% compared to 76.6% in the same period last year and surpassing the consensus projection of 79.9%.

Looking forward, Eli Lilly expects its full-year 2024 EPS outlook to be between $13.50 and $14.00, well above the estimated $12.50.

The company also hiked its revenue forecast for the year to between $42.4 billion and $43.6 billion, compared to a consensus of $41.44 billion.

This upward revision, an increase of roughly $2 billion from the previous forecast, is primarily attributed to the strong performance of its drugs Mounjaro and Zepbound, as well as expanded production capabilities for the rest of the year.

"Lilly's first quarter performance reflects solid year-over-year revenue growth with strong sales of Mounjaro and Zepbound," said David A. Ricks, Lilly's chair and CEO.

"Our progress in addressing some of the world's most significant health care challenges has resulted in increased demand for our medicines.”

Kenyataan:
Kandungan artikel ini tidak mewakili pandangan laman web FxGecko. Kandungan adalah untuk rujukan sahaja dan bukan merupakan nasihat pelaburan. Pelaburan adalah berisiko, pilih dengan teliti! Jika terdapat sebarang isu berkaitan kandungan, hak cipta, dsb., sila hubungi kami dan kami akan membuat pelarasan secepat mungkin!

Artikel Berkaitan

您正在访问的是FxGecko网站。 FxGecko互联网及其移动端产品是中国香港特别行政区成立的Hitorank Co.,LIMITED旗下运营和管理的一款面向全球发行的企业资讯査询工具。

您的IP为 中国大陆地区,抱歉的通知您,不能为您提供查询服务,还请谅解。请遵守当地地法律。